retatrutide temperature VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide Dosage Guide 2026: Phase

10.1016/j.it.2009.09.002 144

Kettle, A.J., et al., Oxidation contributes to low glutathione in the airways of children with cystic fibrosis

10.1078/0944-7113-00262 133 SkonerD

With seven additional Phase 3 readouts expected in 2026, we believe retatrutide could become an important option for patients with significant weight loss needs and certain complications, including knee osteoarthritis." TRIUMPH-4 Efficacy Estimand Results In additional secondary endpoints, retatrutide reduced known markers of cardiovascular risk, including non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein (hsCRP), and at the highest dose lowered systolic blood pressure by 14.0 mmHg, using the efficacy estimand